EUCTR2006-001977-17-DE进行中（未招募）不适用
An open-label, randomized, parallel group study comparing the efficacy and safety of Amlodipine in combination with Valsartan compared to Losartan in combination with Hydrochlorothiazide given for 52 weeks on the regression of left ventricular hypertrophy in patients with mild-to-moderate hypertension - Examine LVH
ovartis Pharma GmbH0 个研究点开始时间: 2006年7月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Caucasian; male or female outpatients and age between 18-80 years of age, inclusive.
- •2.Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy (limited to one active compound) and with a MSDBP of >=90 and <= 110mmHg at visit 1
- •with a combination therapy (limited to up to 3 active compounds; patients treated with 3 active compounds can only be included when all the three compounds were not already given in the highest approved dose level prior to study entry) and with a MSDBP of >=90 and <= 105mmHg at visit 1. Patients who are currently not treated with antihypersensitive drugs may be included with a MSDBP of >=95 and <=110mmHg at visit 1.
- •3.Patients with LVH (LVWT >= 12.0mm and <= 16.0mm; determined by the highest value either by the posterior wall thickness [PWTd] or by the interventricular septal wall thickness [IVSTd]) confirmed by ECHO at Visit 2 prior to randomization.
- •4.Patients who are eligible, able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known or suspected contraindications as listed in the national prescribing information, to any of the study drugs (valsartan, losartan, amlodipine and HCTZ; Appendices 3-6) or to drugs with similar chemical structures or to drugs belonging to the same therapeutic class.
- •2.Severe refractory hypertension defined as confirmed reading of MSSBP > 180 mm Hg or MSDBP of > 110 mm Hg at any visit.
- •3.History of secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing’s disease, pheochromocytoma, polycystic kidney disease, etc..
- •4.Hypertrophic cardiomyopathies due to etiologies other than hypertension (i.e., idiopathic or valvular). Hemodynamically significant mitral stenosis or lesions of the left ventricular outflow tract including aortic stenosis or hypertrophic obstructive cardiomyopathy.
- •5.History of symptomatic heart failure (NYHA classes II-IV) or a LVEF < 50% confirmed by ECHO prior to randomization.
- •6.A history of stroke, transient ischemic cerebral attack, hypertensive encephalopathy, coronary artery bypass surgery, percutaneous transluminal angioplasty or myocardial infarction anytime prior to visit 1.
- •7.Concurrent life threatening arrhythmia or symptomatic arrhythmia.
- •8.Known history of angioneurotic oedema.
- •9.Evidence of hepatic disease or cholestasis as determined by any one of the following: AST (SGOT) or ALT (SGPT) values exceeding 3 x ULN at Visit 1.
- •10.Insulin dependent Diabetes mellitus or uncontrolled treated Type 2 Diabetes mellitus with poor glucose control defined as HbA1c > 7.0 % at Visit 1.
- •11.Documented history of clinically significant peripheral edema.
- •12.Second or third degree heart block, sick sinus syndrome or sinuatrial block.
- •13.Patients with non-sinus rhythm or frequent extrasystoles (>6/min).
- •14.Known or suspected contraindication for MRI
- •use of pacemakers, ICD, defibrillators or any device which interferes with an MRI or presence of cranial aneurysm clips or ocular metallic shards.
- •Patients who cannot lie supine for at least 30 minutes, who cannot hold their breath for 15 seconds, who are suffering from significant claustrophobia (not responsive to light intravenous anxiolytics or whose body structure (e.g., weight, height, body circumference, etc.) exceeds the restrictions of the local MRI site instrument.
- •15.Significant non-cardiovascular illness or condition likely to result in death prior to trial completion, e.g., major organ transplant (life expectancy < 1 year).
- •16.History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- •17.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.
- •18.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml).
- •19.Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural
研究者
相似试验
进行中（未招募）
不适用
To evaluate the immunogenicity and safety of sarilumab administered as monotherapy in patients with rheumatoid arthritis (RA)MedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-002790-22-HUsanofi-aventis recherche & développement120
进行中（未招募）
不适用
To evaluate the immunogenicity and safety of sarilumab administered as monotherapy in patients with rheumatoid arthritis (RA)MedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-002790-22-EEsanofi-aventis recherche & développement120
进行中（未招募）
1 期
To evaluate the immunogenicity and safety of sarilumab administered as monotherapy in patients with rheumatoid arthritis (RA)MedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-002790-22-CZsanofi-aventis recherche & développement120
进行中（未招募）
3 期
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).on-Hodgkin's LymphomaNon-Hodgkin's LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12610000445077Cephalon Inc436
已完成
不适用
A randomized, open-label, parallel group study to evaluate the efficacy and safety of the oral administration of Bifidobacterium animalis subsp. lactis LKM512 in patients with atopic dermatitisAtopic dermatitisJPRN-UMIN000005695Kyodo Milk Industry Co. Ltd.50